Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis

Xiaofang Sun, Xiaohua Niu, Ruochan Chen, Wenyin He, De Chen, Rui Kang, Daolin Tang – 25 March 2016 – Hepatocellular carcinoma (HCC) is a major cause of cancer‐related death worldwide and currently has the fastest rising incidence of all cancers. Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the only approved systemic therapy for advanced HCC. However, acquired resistance to sorafenib has been found in HCC patients, which results in poor prognosis.

Retracted: Immunoglobulin G4+ B‐cell receptor clones distinguish immunoglobulin G 4‐related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies

Marieke E. Doorenspleet, Lowiek M. Hubers, Emma L. Culver, Lucas J. Maillette de Buy Wenniger, Paul L. Klarenbeek, Roger W. Chapman, Frank Baas, Stan F. van de Graaf, Joanne Verheij, Thomas M. van Gulik, Eleanor Barnes, Ulrich Beuers, Niek de Vries – 25 March 2016 – Immunoglobulin G4 (IgG4)‐related disease (IgG4‐RD) of the biliary tree and pancreas is difficult to distinguish from sclerosing cholangitis and biliary/pancreatic malignancies (CA). An accurate noninvasive test for diagnosis and monitoring of disease activity is lacking.

Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals

Jagpreet Chhatwal, Xiaojie Wang, Turgay Ayer, Mina Kabiri, Raymond T. Chung, Chin Hur, Julie M. Donohue, Mark S. Roberts, Fasiha Kanwal – 25 March 2016 – Oral direct‐acting antivirals (DAAs) represent a major advance in hepatitis C virus (HCV) treatment. Along with recent updates in HCV screening policy and expansions in insurance coverage, treatment demand in the United States is changing rapidly. Our objective was to project the characteristics and number of people needing antiviral treatment and HCV‐associated disease burden in the era of oral DAAs.

Subscribe to